News
Drug Development
FDA
Drug Delivery
Deals
Business
Policy
Cell and Gene Therapy
Weight Loss
Rare Disease
Cancer
Job Trends
Artificial Intelligence
NextGen: Top Start Ups to Watch
Podcasts
Reports
Webinars
Press Releases
All News & Releases
Insights
Jobs
Career Advice
Companies
Hotbeds
More
Best Places to Work
Employer Resources
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Drug Delivery
Deals
Business
Policy
Cell and Gene Therapy
Weight Loss
Rare Disease
Cancer
Job Trends
Artificial Intelligence
NextGen: Top Start Ups to Watch
Podcasts
Reports
Webinars
Press Releases
All News & Releases
Insights
Jobs
Career Advice
Companies
Hotbeds
More
Best Places to Work
Employer Resources
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Search Query
Submit Search
Search Results
Submit
Looking for jobs?
Search jobs
Close
703,257 Results
Type
Article (41171)
Company Profile (255)
Press Release (661831)
Multimedia
Podcasts (49)
Webinars (12)
Section
Business (205511)
Career Advice (2025)
Deals (35571)
Drug Delivery (95)
Drug Development (81375)
Employer Resources (172)
FDA (16230)
Job Trends (14912)
News (347088)
Policy (32645)
Tag
2024 BioCapital Digital (6)
2024 BioForest Digital (1)
2024 BioForest Standard (1)
2024 BioMidwest Digital (7)
2024 BioMidwest Standard (1)
2024 Bio NC Digital (4)
2024 Bio NC Standard (1)
2024 Biotech Bay Standard (18)
2024 Biotech Beach Digital (8)
2024 Biotech Beach Standard (4)
2024 Genetown Digital (5)
2024 Genetown Standard (8)
2024 Lone Star Bio Digital (7)
2024 Pharm Country Digital (5)
2024 Pharm Country Standard (5)
2025 BioForest Digital (1)
2025 Lone Star Bio Digital (5)
2026 BioCapital Standard (1)
2026 BioMidwest Elite (1)
2026 Bio NC Standard (1)
2026 Biotech Bay Standard (1)
2026 Biotech Beach Elite (1)
2026 Genetown Elite (2)
2026 Genetown Standard (1)
2026 Pharm Country Standard (2)
Academia (2624)
Academic (1)
Accelerated approval (5)
Adcomms (20)
Allergies (82)
Alliances (50002)
ALS (87)
Alzheimer's disease (1376)
Antibody-drug conjugate (ADC) (112)
Approvals (16229)
Artificial intelligence (246)
Autoimmune disease (21)
Automation (15)
Bankruptcy (362)
Best Places to Work (11686)
BIOSECURE Act (18)
Biosimilars (104)
Biotechnology (179)
Bladder cancer (61)
Brain cancer (26)
Breast cancer (262)
Cancer (2090)
Cardiovascular disease (167)
Career advice (1690)
Career pathing (29)
CAR-T (143)
Cell therapy (405)
Cervical cancer (19)
Clinical research (66014)
Collaboration (798)
Compensation (509)
Complete response letters (19)
COVID-19 (2610)
CRISPR (37)
C-suite (227)
Cystic fibrosis (100)
Data (2056)
Decentralized trials (2)
Denatured (18)
Depression (39)
Diabetes (256)
Diagnostics (6495)
Digital health (19)
Diversity (9)
Diversity, equity & inclusion (44)
Drug discovery (118)
Drug pricing (96)
Drug shortages (25)
Duchenne muscular dystrophy (91)
Earnings (86520)
Editorial (36)
Employer branding (21)
Employer resources (146)
Events (112612)
Executive appointments (695)
FDA (17415)
Featured Employer (48)
Fibrodysplasia Ossificans Progressiva (1)
Friedreich's ataxia (4)
Frontotemporal dementia (7)
Funding (722)
Gene editing (101)
Generative AI (20)
Gene therapy (288)
GLP-1 (697)
Government (4420)
Grass and pollen (4)
Guidances (51)
Healthcare (18903)
Huntington's disease (23)
IgA nephropathy (24)
Immunology and inflammation (109)
Indications (26)
Infectious disease (2751)
Inflammatory bowel disease (133)
Inflation Reduction Act (8)
Influenza (51)
Intellectual property (92)
Interviews (311)
IPO (16553)
IRA (40)
Job creations (3645)
Job search strategy (1437)
Kidney cancer (9)
Labor market (36)
Layoffs (460)
Leadership (16)
Legal (7917)
Liver cancer (72)
Lung cancer (303)
Lymphoma (139)
Machine learning (5)
Management (58)
Manufacturing (283)
MASH (62)
Medical device (13376)
Medtech (13381)
Mergers & acquisitions (19531)
Metabolic disorders (655)
Multiple sclerosis (76)
NASH (16)
Neurodegenerative disease (83)
Neuropsychiatric disorders (24)
Neuroscience (1884)
NextGen: Class of 2025 (6558)
Non-profit (4523)
Northern California (2538)
Now hiring (38)
Obesity (353)
Opinion (205)
Ovarian cancer (73)
Pain (80)
Pancreatic cancer (81)
Parkinson's disease (147)
Partnered (21)
Patents (223)
Patient recruitment (99)
Peanut (46)
People (57693)
Pharmaceutical (64)
Pharmacy benefit managers (18)
Phase I (20588)
Phase II (29069)
Phase III (21643)
Pipeline (1117)
Policy (128)
Postmarket research (2571)
Preclinical (8795)
Press Release (64)
Prostate cancer (98)
Psychedelics (30)
Radiopharmaceuticals (248)
Rare diseases (372)
Real estate (5958)
Recruiting (65)
Regulatory (22304)
Reports (46)
Research institute (2387)
Resumes & cover letters (352)
Rett syndrome (4)
RNA editing (4)
RSV (42)
Schizophrenia (65)
Series A (125)
Series B (81)
Service/supplier (11)
Sickle cell disease (52)
Southern California (2192)
Special edition (14)
Spinal muscular atrophy (150)
Sponsored (28)
Startups (3621)
State (2)
Stomach cancer (13)
Supply chain (65)
Tariffs (24)
The Weekly (29)
United States (22083)
Vaccines (670)
Venture capitalists (38)
Weight loss (229)
Women's health (35)
Worklife (16)
Date
Today (94)
Last 7 days (484)
Last 30 days (2456)
Last 365 days (33132)
2025 (9239)
2024 (35391)
2023 (40275)
2022 (51392)
2021 (55968)
2020 (54354)
2019 (46825)
2018 (35221)
2017 (32380)
2016 (31795)
2015 (37883)
2014 (31578)
2013 (26747)
2012 (28919)
2011 (29582)
2010 (27651)
Location
Africa (729)
Alabama (52)
Alaska (7)
Arizona (229)
Arkansas (13)
Asia (38169)
Australia (6273)
California (5809)
Canada (1940)
China (492)
Colorado (253)
Connecticut (263)
Delaware (134)
Europe (82615)
Florida (860)
Georgia (202)
Idaho (57)
Illinois (515)
India (25)
Indiana (301)
Iowa (9)
Japan (150)
Kansas (102)
Kentucky (23)
Louisiana (9)
Maine (62)
Maryland (863)
Massachusetts (4348)
Michigan (215)
Minnesota (380)
Mississippi (2)
Missouri (79)
Montana (27)
Nebraska (25)
Nevada (60)
New Hampshire (62)
New Jersey (1659)
New Mexico (29)
New York (1653)
North Carolina (939)
North Dakota (7)
Northern California (2538)
Ohio (195)
Oklahoma (14)
Oregon (34)
Pennsylvania (1307)
Puerto Rico (11)
Rhode Island (30)
South America (1108)
South Carolina (20)
South Dakota (1)
Southern California (2192)
Tennessee (100)
Texas (866)
Utah (172)
Virginia (135)
Washington D.C. (59)
Washington State (534)
West Virginia (3)
Wisconsin (51)
703,257 Results for "molecular biosystems inc".
Filters
Sort By
Relevance
Relevance
Newest
Oldest
Collaboration
Lilly Hops On Hot Molecular Glue Train With $1.2B+ Magnet Deal
The molecular glue space has attracted several Big Pharma players over the past few years, including Novo Nordisk, Pfizer and Novartis.
February 28, 2025
·
2 min read
·
Tristan Manalac
Press Releases
Leica Biosystems Announces Partnership With Molecular Instruments As HCR™ Pro RNA-ISH Technology Is Released On The BOND RX and BOND RXm Research Staining Instruments
January 23, 2025
·
3 min read
Lone Star Bio
Molecular Templates, Inc. Provides Interim Update
Molecular Templates, Inc. today provided an update on its clinical-stage programs.
June 3, 2024
·
7 min read
Drug Development
Molecular Glue Degraders at Inflection Point as Pharma Dives In
Novartis, Biogen, Takeda and Novo Nordisk are all betting on advances in the molecular glue degraders space, collectively investing billions in hopes of treating cancer, Alzheimer’s disease, cardiometabolic disease and more.
December 16, 2024
·
6 min read
·
Kate Goodwin
Press Releases
Revive Therapeutics Announces Acquisition of Molecular Hydrogen Program
April 1, 2025
·
5 min read
Press Releases
Zevra Announces Publication of MIPLYFFA® Mechanism of Action Manuscript in Molecular Genetics and Metabolism
April 17, 2025
·
8 min read
Drug Development
Molecular Templates, Inc. Provides Interim Update
Molecular Templates, Inc. today provided an update on its programs.
March 4, 2024
·
9 min read
Business
Molecular Templates, Inc. Reports First Quarter 2024 Financial Results and Corporate Update
Molecular Templates, Inc. (Nasdaq: MTEM, “Molecular Templates,” or “MTEM”), a clinical-stage biopharmaceutical company focused on the discovery and development of proprietary targeted biologic therapeutics, engineered toxin bodies (“ETBs”), to create novel therapies with potent differentiated mechanisms of action, today reported financial results and business updates for the first quarter of 2024.
May 15, 2024
·
6 min read
Press Releases
T2 Biosystems Announces Extension of Multi-Year Capital Equipment Supplier Agreement with Vizient, Inc.
December 16, 2024
·
4 min read
Press Releases
AMDI Launches Autolab™ HBH at ESCMID 2025, Redefining Sample Prep for Molecular Diagnostics
April 14, 2025
·
1 min read
1 of 70,326
Next
